Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. 2013; p. 5.
   Google Scholar
• Polanczyk G, De Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–948.
   PubMed Web of Science ®Google Scholar
• Mortensen PB, Frydenberg M, Thomsen PH. Conduct problems, gender and adult psychiatric outcome of children with attention-deficit hyperactivity disorder. Br J Psychiatry. 2002;181(5):416–421.
   Google Scholar
• Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry. 1996;53(5):437–446.
   PubMed Web of Science ®Google Scholar
• Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. Eur Child Adolesc Psychiatry. 2010;19(4):325–340.
   PubMed Web of Science ®Google Scholar
• Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15(8):476–495.
   PubMed Web of Science ®Google Scholar
• Kordon A, Stollhoff K, Niederkirchner K, et al. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH. Postgrad Med. 2011;123(5):27–38.
   PubMed Web of Science ®Google Scholar
• Wolff C, Alfred A, Lindermüller A, et al. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study. Curr Med Res Opin. 2011;27(sup2):35–44.
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Straughn AB, Patrick KS, et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet. 2003;42(4):393–401.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353–364.
   PubMed Web of Science ®Google Scholar
• Oner O, Turkcapar H, Isli F, et al. Attention deficit hyperactivity disorder treatment Practice in Turkey. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. 2016;26(3):265–272.
   Web of Science ®Google Scholar
• Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60(2):204–211.
   PubMed Web of Science ®Google Scholar
• Sonuga-Barke EJ, Swanson JM, Coghill D, et al. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry. 2004;4(1):28.
   Google Scholar
• Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):883–892.
   PubMed Web of Science ®Google Scholar
• Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006;160(1):82–90.
   PubMedGoogle Scholar
• Ardic UA, Ercan ES, Ercan E, et al. Osmotic release oral system methylphenidate is more effective than immediate release methylphenidate: a retrospective chart review in Turkish children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. 2014;24(4):342–349.
   Web of Science ®Google Scholar
• Öç ÖY, Aǧaoǧlu B, Karakaya I, et al. Efficiency and tolerability of OROS-methylphenidate in Turkish children and adolescents with attention-deficit/hyperactivity disorder. Am J Psychiatry. 2010;11(1):44–50.
   Google Scholar
• Fischer R, Schütz H, Grossmann M, et al. Bioequivalence of a methylphenidate hydrochloride extended-release preparation: comparison of an intact capsule and an opened capsule sprinkled on applesauce. Int J Clin Pharmacol Ther. 2006;44(3):135–141.
   Web of Science ®Google Scholar
• Döpfner M, Gerber WD, Banaschewski T, et al. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry. 2004;13(1):i93–i101.
   Google Scholar
• Döpfner M, Ose C, Fischer R, et al. Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet® retard and Concerta® – a randomized, controlled, double-blind multicenter clinical crossover trial. J Child Adolesc Psychopharmacol. 2011;21(5):445–454.
   Web of Science ®Google Scholar
• Gökler B, Ünal F, Pehlivantürk B, et al. Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version-Turkish version (K-SADS-PL-T). Turk J Child Adolesc Mental Health. 2004;11(3):109–116.
   Google Scholar
• Weiss M, Dickson R, Wasdell M, et al., editors. Weiss functional impairment rating scale-parent report (WFIRS-P). American Psychiatric Association 158th Annual Meeting; 2005.
   Google Scholar
• Tarakçıoğlu MC, Memik NC, Olgun NN, et al. Turkish validity and reliability study of the Weiss functional impairment rating scale-parent report. ADHD Attention Deficit Hyperactivity Disord. 2015;7(2):129–139.
   Web of Science ®Google Scholar
• Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86(2):184–192.
   PubMed Web of Science ®Google Scholar
• Hechtman L, Abikoff H, Klein RG, et al. Children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment: impact on parental practices. J Am Acad Child Adolesc Psychiatry. 2004;43(7):830–838.
   Web of Science ®Google Scholar
• Abikoff H, Hechtman L, Klein RG, et al. Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004;43(7):820–829.
   PubMed Web of Science ®Google Scholar
• Bastiaens L. Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic. Psychiatr Q. 2008;79(2):133–137.
   PubMed Web of Science ®Google Scholar
• Sonuga-Barke EJ, Coghill D, DeBacker M, et al. Measuring methylphenidate response in attention-deficit/hyperactivity disorder: how are laboratory classroom-based measures related to parent ratings? J Child Adolesc Psychopharmacol. 2009;19(6):691–698.
   PubMed Web of Science ®Google Scholar
• Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs study). Pediatrics. 2004;113(3):e206–e216.
   PubMed Web of Science ®Google Scholar
• Owens EB, Hinshaw SP, Kraemer HC, et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol. 2003;71(3):540–552.
   PubMed Web of Science ®Google Scholar
• Cop E, Oner O, Yurtbasi P, et al. Effects of maternal symptom ratings and other clinical features on short-term treatment response to OROS methylphenidate in children and adolescents with ADHD in a naturalistic clinical setting. Klinik Psikofarmakoloji Bülteni – Bull Clin Psychopharmacol. 2016;26(2):126–133.
   Web of Science ®Google Scholar
• Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40(2):180–187.
   PubMed Web of Science ®Google Scholar
• Rapport MD, Randall R, Moffitt C. Attention-Deficit/Hyperactivity disorder and methylphenidate: a dose-response analysis and parent-child comparison of somatic complaints. J Atten Disord. 2002;6(1):15–24.
   Google Scholar
• Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112(5):e404–e404.
   PubMed Web of Science ®Google Scholar
• Lee J, Grizenko N, Bhat V, et al. Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. BMC Psychiatry. 2011;11(1):70.
   Google Scholar
• Zhu J, Spencer TJ, Liu-Chen L-Y, et al. Methylphenidate and μ opioid receptor interactions: a pharmacological target for prevention of stimulant abuse. Neuropharmacology. 2011;61(1-2):283–292.
   PubMed Web of Science ®Google Scholar
• Trigo JM, Martin-García E, Berrendero F, et al. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend. 2010;108(3):183–194.
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Schoedel KA, Schuller R, et al. Do formulation differences alter abuse liability of methylphenidate?: a placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol. 2007;27(5):459–467.
   PubMed Web of Science ®Google Scholar